CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $333 | +66.5% | 11,300 | 0.0% | 0.00% | – |
| Q2 2023 | $200 | +13.0% | 11,300 | 0.0% | 0.00% | – |
| Q1 2023 | $177 | -14.1% | 11,300 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $206 | -99.9% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $214,000 | +8.1% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $198,000 | -7.9% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $215,000 | -22.1% | 11,300 | +9.7% | 0.00% | 0.0% |
| Q4 2021 | $276,000 | +34.6% | 10,300 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $205,000 | +9.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $187,000 | +21.4% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $154,000 | +19.4% | 10,000 | 0.0% | 0.00% | – |
| Q4 2020 | $129,000 | -60.9% | 10,000 | -9.1% | 0.00% | -100.0% |
| Q4 2018 | $330,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |